Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID

Details for Australian Patent Application No. 2003243152 (hide)

Owner BRISTOL-MYERS SQUIBB COMPANY

Inventors Hagerty, David; Becker, Jean-Claude; Carr, Suzette; Peach, Robert J.; Cohen, Robert

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2003243152

PCT Number PCT/US03/12356

PCT Pub. Number WO2003/088991

Priority 60/373,852 19.04.02 US; 60/407,246 30.08.02 US

Filing date 18 April 2003

Wipo publication date 3 November 2003

International Classifications

A61K 038/16 Medicinal preparations containing peptides - Peptides having more than 20 amino acids

C07K 014/705 Peptides having more than 20 amino acids

Event Publications

11 September 2003 Complete Application Filed

  Priority application(s): 60/373,852 19.04.02 US; 60/407,246 30.08.02 US

11 December 2003 Application Open to Public Inspection

  Published as AU-A-2003243152

30 July 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003243153-NOVEL CRYSTALLINE POLYMORPH FORM-VI OF OLANZAPINE AND A PROCESS FOR PREPARATION THEREOF

2003243151-NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 251P5G2 USEFUL IN TREATMENT AND DETECTION OF CANCER